Article Information
- Received May 12, 2016
- Revision received January 15, 2017
- Accepted January 17, 2017
- Published online February 13, 2017.
Author Information
- Kert Mätlik1,
- Helena Vihinen2,
- Ali Bienemann3,
- Jaan Palgi4,
- Merja H. Voutilainen1,
- Sigrid Booms5,
- Maria Lindahl1,
- Eija Jokitalo2,
- Mart Saarma1,
- Henri J. Huttunen5,6,
- Mikko Airavaara1 and
- Urmas Arumäe1,4
- 1Program in Developmental Biology, Institute of Biotechnology, University of Helsinki, 00014 Helsinki, Finland
- 2Electron Microscopy Unit, Institute of Biotechnology, University of Helsinki, 00014 Helsinki, Finland
- 3Functional Neurosurgery Research Group, Learning and Research Building, School of Clinical Sciences, Southmead Hospital, University of Bristol, Bristol BS10 5NB, United Kingdom
- 4Department of Gene Technology, Tallinn University of Technology, 12618 Tallinn, Estonia
- 5 Herantis Pharma Plc, 00790 Helsinki, Finland
- 6Neuroscience Center, University of Helsinki, 00014 Helsinki, Finland
- Correspondence should be addressed to Kert Mätlik, Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014 Helsinki, Finland. E-mail: kert.matlik{at}helsinki.fi.
Author contributions
Author contributions: K.M., H.V., M.H.V., S.B., E.J., H.J.H., M.A., and U.A. designed research; K.M., H.V., A.B., J.P., and M.A. performed research; M.L. and M.S. contributed unpublished reagents/analytic tools; K.M., H.V., A.B., S.B., E.J., H.J.H., M.A., and U.A. analyzed data; K.M. and U.A. wrote the paper.
Disclosures
M.H.V. and M.S. are inventors in a cerebral dopamine neurotrophic factor-related patent application that is owned by Herantis Pharma Plc. S.B. and H.J.H. are employees and shareholders of Herantis Pharma Plc. M.S. is a shareholder of Herantis Pharma Plc.
This study was financed from the Academy of Finland Program 11186236 (Finnish Centre of Excellence Program 2008–2013), The Finnish Funding Agency for Technology and Innovation (Tekes; Project 1505/31/10), European Union through the European Social Fund (Mobilitas Grant MTT84) and Estonian Research Council Grant PUT110. M.A. was supported by Academy of Finland Grants 250275 and 256398, and the Sigrid Jusélius Foundation. K.M. was supported by the Finnish Graduate School of Neuroscience and the Ella and Georg Ehrnrooth Foundation. M.S. was supported by Jane and Aatos Erkko Foundation.
Funding
Academy of Finland
11186236Finnish Funding Agency of technology and innovation
1505/31/10European Social Fund, EU
MTT84Estonian Research Council
PUT110Academy of Finland
250275Academy of Finland
256398Sigrid Juselius Foundation
Finnish Graduate School of Neuroscience
Ella and Georg Ehrnrooth Foundation
Other Version
- You are viewing the most recent version of this article.
- previous version (February 13, 2017).
Article usage
In this issue
